The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States

CS Kraft, AL Hewlett, S Koepsell… - Clinical infectious …, 2015 - academic.oup.com
CS Kraft, AL Hewlett, S Koepsell, AM Winkler, CJ Kratochvil, LA Larson, JB Varkey…
Clinical infectious diseases, 2015academic.oup.com
Abstract Background. The current West Africa Ebola virus disease (EVD) outbreak has
resulted in multiple individuals being medically evacuated to other countries for clinical
management. Methods. We report two patients who were transported from West Africa to the
United States for treatment of EVD. Both patients received aggressive supportive care
measures, as well as an investigational therapeutic (TKM-100802) and convalescent
plasma. Results. While one patient experienced critical illness with multi-organ failure …
Abstract
Background.  The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.
Methods.  We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma.
Results.  While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date.
Conclusions.  It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.
Oxford University Press